In a nutshell In this study, researchers examined the effect of epoetin alfa (Epogen; Procrit) on anemia (low count of red blood cells) caused by chemotherapy in breast cancer patients. Some background Breast cancer is caused by a defect that makes some breast cancer cells grow and multiply rapidly. One of the treatment options for patients with...
Read More
In a nutshell In this trial researchers examined whether the use of neoadjuvant chemotherapy (before surgery) influenced survival or recurrence rates in women undergoing breast conserving therapy for breast cancer. Some background Neoadjuvant chemotherapy (NCT) refers to chemotherapy treatments received prior to surgery. This approach is often...
Read MoreIn a nutshell This article looks at two treatment options for people who have obtained a complete, partial or stable state disease after first round combination chemotherapy for metastatic breast cancer. Some background Metastatic breast cancer is cancer that has spread from the breast to distant organs or tissues in the body. Treatment for...
Read MoreIn a nutshell This study compared survival rates of patients who developed cancer in both breasts (called contralateral breast cancer or CBC) and patients who had cancer in one breast (unilateral breast cancer or UBC). Some background Breast cancer is the most common cancer among women. Breast cancer survivors are 3.5 times more likely to develop...
Read More
In a nutshell This phase II clinical trial tested whether a new drug, entinostat, can work in concert with exemestane (a hormone therapy drug), to fight breast cancer that no longer responds to hormone therapy alone. Some background Some breast cancers need estrogen (a female sex hormone) to grow. These breast cancer cells respond to estrogen via...
Read More
In a nutshell This paper looks at the use of a system called EPclin that gives patients a risk score according to the clinical and genetic characteristics of their tumor. This score is used to predict if patients are at high or low risk of distant reccurrence of the tumor and if they would benefit from chemotherapy. Some background...
Read More
In a nutshell This study evaluated the risk of heart disease associated with two commonly prescribed treatments for breast cancer. The main finding was that Trastuzumab (Herceptin) and Anthracycline (Adriamycin/Daunomycin) treatments are associated with a higher risk of heart failure or ‘cardiomyopathy’. Some background Anthracyclines...
Read More
The present review discusses the principles, methods and complications of breast reconstruction surgery for breast cancer patients who need mastectomy (surgical removal of the entire breast). Women with breast cancer often need extensive surgeries to eliminate the cancer, along with healthy breast tissue, skin or the nipple and areola (the darker area...
Read MoreIn a nutshell The present study evaluated the relationship between high insulin levels in the blood stream and the risk of cancer-related mortality. Its authors report that women with higher-than-normal insulin levels are at higher risk of death due to breast cancer. Some background Breast cancer has been shown to be more common in people who...
Read MoreIn a nutshell This study evaluated if strategies to prevent cancer recurrence are associated with prolonged survival 15 years after treatment. Their main findings were that postoperative radiation managed to prevent cancer recurrence and was associated with higher rates of long-term survival. Some background Early breast cancer is often treated...
Read MoreIn a nutshell The present study examined the association between obesity and survival rates by breast cancer subtypes. They found that survival rates were lower in obese patients, particularly in women whose tumors were hormone receptor positive and HER2 negative. Some background Obesity is defined as a Body Mass...
Read More
This paper reviews chemotherapy options for triple-negative breast cancers. Breast cancer cells express 3 main receptors that can be targeted with therapy: Estrogen receptors (ER), Progesterone receptors (PR) and HER2. Triple-negative breast cancers (TNBCs) do not express these 3 receptors and make up approximately 15% of breast cancers. Such tumors do...
Read More
